DERM (Journey Medical Corporation Common Stock) Stock Analysis - Politician Trades

Journey Medical Corporation Common Stock (DERM) is a publicly traded Healthcare sector company. As of May 21, 2026, DERM trades at $6.17 with a market cap of $172.09M and a P/E ratio of -16.63. DERM moved +0.08% today. Year to date, DERM is -13.34%; over the trailing twelve months it is -10.32%. Its 52-week range spans $3.54 to $9.56. Analyst consensus is strong buy with an average price target of $13.50. Rallies surfaces DERM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded DERM stock?

Rallies tracks politician and congressional stock disclosures for DERM, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

DERM Key Metrics

Key financial metrics for DERM
MetricValue
Price$6.17
Market Cap$172.09M
P/E Ratio-16.63
EPS$-0.37
Dividend Yield0.00%
52-Week High$9.56
52-Week Low$3.54
Volume0
Avg Volume0
Revenue (TTM)$64.68M
Net Income$-9.59M
Gross Margin65.44%

Latest DERM News

Recent DERM Insider Trades

  • Maraoui Claude sold 4.83K (~$33.06K) on May 2, 2025.
  • Benesch Joseph sold 2.41K (~$16.48K) on May 2, 2025.
  • Alloush Ramsey sold 2.86K (~$19.54K) on May 2, 2025.

DERM Analyst Consensus

4 analysts cover DERM: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.50.

Common questions about DERM

Which politicians traded DERM stock?
Rallies tracks politician and congressional stock disclosures for DERM, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in DERM?
Yes. Rallies tracks politician and congressional stock disclosures for DERM, including reported purchases, sales, dates, owners, and trade amounts when available.
Is DERM research on Rallies investment advice?
No. Rallies provides research, data, and educational context for DERM. It does not provide personalized investment advice.
DERM

DERM